NewsBenzinga길리어드 사이언스, PBC 치료제 리브델지 IDEAL 3상 성공 발표···52주차 ALP 정상화 75.4% 달성, 위약군 16.1% 대비 우수한 결과 및 중대한 이상반응 발생률 3.1%로 위약군 12.9% 대비 낮은 수치, 약물 관련 이상반응은 없어 길리어드 사이언스, PBC 치료제 리브델지 IDEAL 3상 성공 발표···52주차 ALP 정상화 75.4% 달성, 위약군 16.1% 대비 우수한 결과 및 중대한 이상반응 발생률 3.1%로 위약군 12.9% 대비 낮은 수치, 약물 관련 이상반응은 없어 Benzinga 2026.11.05 15:05 (GMT+0) Open on Benzinga Other news Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why Binance Plans to Expand into Five Asian Markets Next Year, Focusing on South and Southeast Asia Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated
Salesforce Issues Security Advisory On Third-Party Optimizely Script Incident Affecting Certain Salesforce-Branded Sites; Optimizely Scripts Being Confirmed Disabled
FBI Reissues Warning About AI-Powered Cyberattacks on Businesses as Crypto Bettors Dismiss AI Link to FAA Outage
SpaceX, Meta and Nebius Stand to Benefit From Nvidia’s ‘Fastest Product Ramp’ Yet: Strategist Shay Boloor Explains Why
Innate Pharma Reports IPH4502 Phase 1 Data Across 76 Patients: Maximum Tolerated Dose 3.6 Mg/Kg Q3W, Grade 3+ TEAEs In 43.4%, Stomatitis Only Dose-Limiting Toxicity
Olema Reports Selective KAT6A Degraders Potently Inhibit Proliferation In Diverse ER+/HER2- Breast Cancer Models, Active In ESR1-Mutant And Wild-Type, Well-Tolerated